argenx announces results of Annual General Meeting of Shareholders
May 10, 2022 17:30 ET
|
argenx SE
May 10, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022 01:00 ET
|
argenx SE
$21.2 million in VYVGART® (efgartigimod alfa-fcab) net product sales during initial quarter of U.S. commercial launchMet primary endpoint in Phase 3 ADVANCE trial of VYVGART for treatment of primary...
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
May 05, 2022 01:00 ET
|
argenx SE
Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types...
argenx to Present at BofA Securities 2022 Healthcare Conference
May 04, 2022 01:00 ET
|
argenx SE
May 4, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
April 28, 2022 01:00 ET
|
argenx SE
April 28, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
April 05, 2022 01:00 ET
|
argenx SE
Interim data suggest long-term treatment with VYVGART provides improvement in generalized myasthenia gravis (gMG) disease scores that remains consistent over multiple treatment cycles ...
argenx announces full exercise of underwriters’ option to purchase additional ADSs
March 29, 2022 17:00 ET
|
argenx SE
Regulated information — Inside information March 29, 2022, 11:00 PM CETMarch 29, 2022, 5:00 PM ET Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...
argenx announces Annual General Meeting of Shareholders on May 10, 2022
March 29, 2022 16:30 ET
|
argenx SE
March 29, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx announces closing of global offering
March 28, 2022 16:30 ET
|
argenx SE
Regulated information March 28, 2022, 10:30 PM CETMarch 28, 2022, 4:30 PM ET Breda, the Netherlands / Ghent, Belgium — argenx SE (Euronext & Nasdaq: ARGX), a global immunology...
argenx raises $700 million in gross proceeds in a global offering
March 23, 2022 21:00 ET
|
argenx SE
Regulated information — Inside information March 23, 2022, 9:00 PM ET March 24, 2022, 2:00 AM CET Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global...